Fortitude Biomedicines, a private biotechnology company, has secured $13.0 million in funding from investors. This capital infusion marks a significant milestone for the Waltham, Massachusetts-headquartered firm, which is pioneering next-generation immune cell targeting biologics and an antibody鈥揹rug conjugate (ADC) platform.
The company's innovative approach integrates the precision targeting of ADCs with the catalytic power of targeted protein degradation, utilizing proprietary molecular glue payloads. Fortitude Biomedicines is developing transformative therapies designed to expand the therapeutic window of ADCs, overcome resistance mechanisms, and unlock new target space, addressing critical challenges in medicine.
This funding round will enable Fortitude Biomedicines to accelerate its research and development initiatives. The capital is planned to be used for advancing its differentiated pipeline of biologics and ADCs, further strengthening its robust discovery engine. The investment underscores confidence in the company's scientific foundation and its potential to bring novel treatments to patients.
With this investment, Fortitude Biomedicines is well-positioned to continue its mission. The company aims to leverage its experienced team of drug hunters to build out its pipeline and deliver meaningful benefits to patients with high unmet medical need, driving forward its growth plans in the biotechnology sector.
.png&w=3840&q=75)
